MAVS Antibody (Rabbit mAb) [H8N11]

CatNo: F5024

    Application: Reactivity:
    • Lane 1: A549, Lane 2: MCF-7, Lane 3: PC3
    • Immunofluorescent analysis of MCF-7 cells using F5024 (green, 1:100 ), Hoechst (blue) and tubulin (Red).
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:50
    1:100 - 1:400
    1:200 - 1:800
    Application
    WB, IP, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    56 kDa
    ポジティブコントロール MCF7 cells; THP-1 cells; A549 cells; RT4 cells; PC-3 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    MAVS Antibody (Rabbit mAb) [H8N11] detects endogenous levels of total MAVS protein.
    タンパク質の局在
    細胞内膜系、ミトコンドリア、ミトコンドリア外膜、ペルオキシソーム
    Uniprot ID
    Q7Z434
    Clone
    H8N11
    Synonym(s)
    Mitochondrial antiviral-signaling protein, MAVS, Virus-induced-signaling adapter (VISA), MAVS, IPS1, KIAA1271, VISA
    Background
    MAVS (mitochondrial antiviral‑signaling protein; also VISA/IPS‑1/Cardif) is a CARD‑containing adaptor anchored in the outer mitochondrial membrane and related organellar membranes, where it functions as the central signaling hub for RIG‑I‑like receptor detection of viral RNA, converting transient cytosolic sensor engagement into prion‑like signaling assemblies that drive IRF and NF‑κB activation and type I interferon production. The protein architecture combines an N‑terminal CARD that mediates homotypic interactions with the CARDs of RIG‑I and MDA5, a proline‑rich central segment that recruits TRAF E3 ligases and other scaffolds, and a C‑terminal transmembrane helix that anchors MAVS to mitochondria, peroxisomes, and mitochondria‑associated ER membranes, placing the signaling platform at strategically positioned intracellular sites. Upon sensing viral RNA, RIG‑I/MDA5 undergo K63‑linked ubiquitination and oligomerization and engages the MAVS CARD, triggering a conformational transition in MAVS into higher‑order, filamentous aggregates with prion‑like properties that self‑propagate along the mitochondrial network and nucleate large signaling complexes containing TRAF2/3/5/6, TANK, TBK1, and the IKKα/β/γ complex. These assemblies drive phosphorylation of IRF3/IRF7 and IκB, leading to nuclear translocation of IRF and NF‑κB transcription factors and the coordinated induction of type I and III interferons, pro‑inflammatory cytokines, and antiviral effector genes, and MAVS‑dependent pathways also intersect with apoptotic machinery via caspase‑8 to eliminate infected cells. Genetic ablation of MAVS in mice abolishes RIG‑I/MDA5‑mediated IFN induction and IRF3/NF‑κB activation in most cell types, renders animals unable to mount effective innate responses to RNA viruses, and results in high viral loads and lethality after poly(I:C) challenge or infection with multiple RNA viruses, while leaving TLR‑ and cytosolic DNA–dependent IFN pathways largely intact, demonstrating that MAVS is specifically essential for the RLR arm of antiviral immunity. Post‑translational control of MAVS, particularly ubiquitylation, provides additional layers of signal tuning: K63‑linked ubiquitination by several E3 ligases (including TRIM31 and MARCH5) promotes MAVS aggregation and signaling competence, whereas K48‑linked ubiquitination by ligases such as RNF125 targets MAVS for proteasomal degradation and terminates signaling, and a growing set of deubiquitylating enzymes removes these chains to reset the pathway, collectively making the ubiquitylation status of MAVS a critical determinant of amplitude and duration of the antiviral response. Multiple RNA and DNA viruses—including HCV, picornaviruses, and herpesviruses—encode proteases or mitochondrial modulators that cleave or displace MAVS from membranes, disrupt its aggregation, or manipulate its ubiquitylation, underlining the adaptor’s central position at the host–virus interface and highlighting MAVS as both a vulnerability targeted by pathogens and a potential therapeutic node for modulating innate immunity and inflammatory pathology beyond classic viral infection, such as in sepsis and sterile tissue injury.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください